Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study (Q33357108)

26 July 2017

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

David Scott Miller

1

0 references

author name string

John A Blessing

series ordinal

2

1 reference

26 July 2017

Samuel S Lentz

series ordinal

3

1 reference

26 July 2017

D Scott McMeekin

series ordinal

4

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

26 July 2017

1 reference

26 July 2017

98

1 reference

26 July 2017

1664-1669

1 reference

26 July 2017

8

1 reference

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11690

7 January 2021

Identifiers

DOI

10.1002/CNCR.11690

1 reference

26 July 2017

1 reference